MPs urge Government to review regulations for direct-to-consumer genetic testing
By Science and Technology Committee,
UK Parliament
| 06. 22. 2021
The popularity of genomics tests sold directly to consumers has increased in recent years, with products focusing on ancestry, health outcomes and genetic traits. Today, the Science and Technology Committee publishes its Direct-to-consumer genomic testing Report, urging policymakers to seize opportunities and address risks posed by the increasing availability and scope of consumer genomic testing.
Drawing on evidence taken from genomic testing companies, healthcare professionals and think tanks, the Committee's Report makes a number of recommendations for the Government to consider when updating regulations, including:
- Pre-market assessment of direct-to-consumer tests by an independent body. This assessment should cover the test's clinical performance (the extent to which it can provide information about treatment of a disease, and the likelihood of improved outcomes) in addition to the current requirement to achieve analytical performance, which describes how well the test can identify the presence of a particular gene.
- The development of technical standards for direct-to-consumer genomic testing, enabling the data generated to be used and relied upon by Genomics England and the NHS. Clearly defining such standards would facilitate research efforts...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...